Survival with Osimertinib plus Chemotherapy in <i>EGFR</i> -Mutated Advanced NSCLC
Among patients with <i>EGFR</i>-mutated advanced NSCLC, first-line treatment with osimertinib plus platinum-pemetrexed led to significantly longer overall survival than osimertinib monotherapy and was associated with an increased risk of reversible adverse events of grade 3 or higher. (Funded by AstraZeneca; FLAURA2 ClinicalTrials.gov number, NCT04035486.).
Authors
- Bivas Biswas (ORCID: https://orcid.org/0000-0002-6101-5500)
- Noriko Yanagitani
- Yuri Rukazenkov
- David Planchard (ORCID: https://orcid.org/0000-0002-1565-8310)
- Pasi Antero Janne (ORCID: https://orcid.org/0000-0002-7821-4928)
- Natalia Valdiviezo (ORCID: https://orcid.org/0000-0002-4300-5958)
- Hiroshi Kagamu
- Carles Escriu (ORCID: https://orcid.org/0000-0003-3638-3202)
- James Chih‐Hsin Yang (ORCID: https://orcid.org/0000-0002-5586-5138)
- Liyan Jiang (ORCID: https://orcid.org/0000-0002-9023-2475)
- Ying L. Liu (ORCID: https://orcid.org/0000-0001-5790-851X)
- Jialei Wang (ORCID: https://orcid.org/0000-0001-8239-8478)
- Chee Khoon Lee (ORCID: https://orcid.org/0000-0003-2955-9820)
- Helen Mann
- Leona Koubková
- Artem Poltoratskiy (ORCID: https://orcid.org/0000-0003-3259-2242)
- Carlos A. Rojas (ORCID: https://orcid.org/0000-0002-1312-1288)
- Elena Armenteros-Monterroso
- Doreen A. Ezeife (ORCID: https://orcid.org/0000-0001-5553-979X)
- Tae Min Kim (ORCID: https://orcid.org/0000-0001-6145-4426)
- Kunihiko Kobayashi (ORCID: https://orcid.org/0000-0003-4319-7512)
- Yeni Nerón
Institutions
- AstraZeneca (United Kingdom) (GB)
- National Taiwan University (TW)
- University of Calgary (CA)
- Shanghai Jiao Tong University (CN)
- Université Paris-Saclay (FR)
- Institut Gustave Roussy (FR)
- Shanghai Chest Hospital (CN)
- Seoul National University Hospital (KR)
- Clatterbridge Cancer Centre NHS Foundation Trust (GB)
- Tata Medical Center (IN)
- Fudan University Shanghai Cancer Center (CN)
- University Hospital in Motol (CZ)
- Jilin Province Tumor Hospital (CN)
- AstraZeneca (Singapore) (SG)
- Institute of Oncology NN Petrov (RU)
- Dana-Farber Cancer Institute (US)
- St George Hospital (AU)
- Instituto Nacional de Enfermedades Neoplásicas (PE)
- National Taiwan University Hospital (TW)
- AstraZeneca (Spain) (ES)
- Centro de Pesquisas Oncológicas (BR)
- Japanese Foundation For Cancer Research (JP)
- Saitama Medical University (JP)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1056/nejmoa2510308
- Citations
- 26
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 39.48